Ironwood Pharmaceuticals Inc
IRWD1.424USD
+0.144+11.25%
交易中 （美东）报价延迟15分钟
231.31M总市值
亏损市盈率 TTM
关于 Ironwood Pharmaceuticals Inc 公司
Ironwood Pharmaceuticals, Inc. 是一家胃肠道 (GI) 医疗保健公司，致力于推进胃肠道疾病的治疗并重新定义胃肠道患者的护理标准。该公司致力于开发 LINZESS（利那洛肽），用于治疗成人便秘性肠易激综合征 (IBS-C) 或慢性特发性便秘 (CIC)。利那洛肽还获准用于治疗 6-17 岁儿童患者的功能性便秘。该公司正在推进阿普拉鲁肽，这是一种长效合成胰高血糖素样肽-2 (GLP-2) 类似物，正在开发用于治疗罕见胃肠道疾病，包括伴有肠衰竭的短肠综合征 (SBS-IF) 以及几种早期资产。该公司正在推进 IW-3300（一种 GC-C 激动剂）的研发，用于治疗内脏疼痛病症，例如间质性膀胱炎/膀胱疼痛综合征 (IC/BPS) 和子宫内膜异位症。该公司还在开发 CNP-104，用于治疗 PBC（一种罕见的针对肝脏的自身免疫性疾病）。
公司简介
公司代码IRWD
公司名称Ironwood Pharmaceuticals Inc
上市日期Feb 03, 2010
CEOMr. Thomas A. (Tom) Mccourt
员工数量253
证券类型Ordinary Share
年结日Feb 03
公司地址100 Summer Street, Suite 2300
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02110
电话16176217722
网址https://www.ironwoodpharma.com/
公司代码IRWD
上市日期Feb 03, 2010
CEOMr. Thomas A. (Tom) Mccourt
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Thomas A. (Tom) Mccourt
Mr. Thomas A. (Tom) Mccourt
Chief Executive Officer, Director
Chief Executive Officer, Director
1.37M
+62.57%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
613.42K
+7.92%
Dr. Michael Shetzline, M.D., Ph.D.
Dr. Michael Shetzline, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
324.29K
-17.25%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
258.10K
+4.76%
Mr. Andrew Dreyfus
Mr. Andrew Dreyfus
Independent Director
Independent Director
233.23K
+23.91%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Independent Chairman of the Board
Independent Chairman of the Board
208.84K
+27.47%
Mr. Jon R. Duane
Mr. Jon R. Duane
Independent Director
Independent Director
190.34K
+30.96%
Mr. John Minardo
Mr. John Minardo
Senior Vice President, Chief Legal Officer, Secretary
Senior Vice President, Chief Legal Officer, Secretary
167.65K
-4.42%
Ms. Marla L. Kessler
Ms. Marla L. Kessler
Independent Director
Independent Director
165.88K
+37.23%
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
117.94K
+61.69%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Thomas A. (Tom) Mccourt
Mr. Thomas A. (Tom) Mccourt
Chief Executive Officer, Director
Chief Executive Officer, Director
1.37M
+62.57%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
613.42K
+7.92%
Dr. Michael Shetzline, M.D., Ph.D.
Dr. Michael Shetzline, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
324.29K
-17.25%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
258.10K
+4.76%
Mr. Andrew Dreyfus
Mr. Andrew Dreyfus
Independent Director
Independent Director
233.23K
+23.91%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Independent Chairman of the Board
Independent Chairman of the Board
208.84K
+27.47%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月21日 周四
更新时间: 8月21日 周四
持股股东
股东类型
持股股东
持股股东
占比
Armistice Capital LLC
9.94%
Sarissa Capital Management, L.P.
9.80%
The Vanguard Group, Inc.
9.61%
BlackRock Institutional Trust Company, N.A.
6.84%
APG Asset Management N.V.
6.80%
其他
57.01%
持股股东
持股股东
占比
Armistice Capital LLC
9.94%
Sarissa Capital Management, L.P.
9.80%
The Vanguard Group, Inc.
9.61%
BlackRock Institutional Trust Company, N.A.
6.84%
APG Asset Management N.V.
6.80%
其他
57.01%
股东类型
持股股东
占比
Hedge Fund
36.08%
Investment Advisor
27.23%
Investment Advisor/Hedge Fund
23.11%
Pension Fund
7.08%
Research Firm
4.06%
Individual Investor
2.91%
Family Office
0.30%
Sovereign Wealth Fund
0.13%
Bank and Trust
0.10%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
583
167.85M
103.73%
-32.54M
2025Q1
598
162.94M
100.73%
-39.13M
2024Q4
595
170.54M
106.57%
-31.05M
2024Q3
583
171.68M
107.49%
-32.57M
2024Q2
576
178.76M
112.46%
-25.68M
2024Q1
583
179.31M
112.83%
-3.43M
2023Q4
563
172.78M
110.50%
-13.64M
2023Q3
560
170.59M
109.32%
-22.08M
2023Q2
550
173.56M
111.70%
-13.28M
2023Q1
553
173.35M
111.59%
-16.83M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Armistice Capital LLC
13.70M
8.47%
+4.23M
+44.70%
Mar 31, 2025
Sarissa Capital Management, L.P.
16.39M
10.13%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
16.20M
10.01%
+995.30K
+6.55%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
10.76M
6.65%
-10.57M
-49.54%
Mar 31, 2025
Renaissance Technologies LLC
9.94M
6.14%
+874.25K
+9.64%
Mar 31, 2025
Acadian Asset Management LLC
2.65M
1.63%
+1.63M
+160.75%
Mar 31, 2025
AQR Capital Management, LLC
2.52M
1.56%
+2.13M
+535.76%
Mar 31, 2025
Two Sigma Investments, LP
3.11M
1.92%
+1.01M
+48.36%
Mar 31, 2025
Kynam Capital Management LP
5.82M
3.6%
+1.14M
+24.27%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
Acquirers Small and Micro Deep Value ETF
1.82%
Inspire Small/Mid Cap ESG ETF
0.37%
Amplify Etho Climate Leadership U.S. ETF
0.15%
Vanguard US Value Factor ETF
0.15%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.1%
iShares Micro-Cap ETF
0.03%
Principal U.S. Small-Cap ETF
0.02%
iShares Biotechnology ETF
0.02%
Schwab Fundamental U.S. Small Company ETF
0.02%
WisdomTree US SmallCap Fund
0.01%
查看更多
Acquirers Small and Micro Deep Value ETF
占比1.82%
Inspire Small/Mid Cap ESG ETF
占比0.37%
Amplify Etho Climate Leadership U.S. ETF
占比0.15%
Vanguard US Value Factor ETF
占比0.15%
SPDR SSGA US Small Cap Low Volatility Index ETF
占比0.1%
iShares Micro-Cap ETF
占比0.03%
Principal U.S. Small-Cap ETF
占比0.02%
iShares Biotechnology ETF
占比0.02%
Schwab Fundamental U.S. Small Company ETF
占比0.02%
WisdomTree US SmallCap Fund
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
